Krystal Biotech KRYS - Options Chain | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Krystal Biotech Inc (KRYS)
Krystal Biotech Inc (KRYS) Options

Krystal Biotech Inc (KRYS)

153.24

-2.51

(-1.61%)

Closed February 17 4:00PM

Delayed by 15 minutes

153.24

-0.37

(-0.24%)

After Hours: 4:03PM

Delayed by 15 minutes

KRYS Options Flow

Calls

Strike	Bid Price	Ask Price	Last Price	Midpoint	Change	Change %	Volume	OPEN INT	Last Trade
105.00	46.50	50.40	0.00	48.45	0.00	0.00 %	0	0	-
110.00	41.50	45.50	40.00	43.50	0.00	0.00 %	0	0	-
115.00	36.50	40.50	0.00	38.50	0.00	0.00 %	0	0	-
120.00	32.00	36.00	0.00	34.00	0.00	0.00 %	0	0	-
125.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
130.00	23.10	26.90	0.00	25.00	0.00	0.00 %	0	0	-
135.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
140.00	15.10	18.90	0.00	17.00	0.00	0.00 %	0	0	-
145.00	15.50	15.50	15.50	15.50	0.00	0.00 %	0	2	-
150.00	6.00	6.00	6.00	6.00	0.00	0.00 %	0	1,002	-
155.00	7.43	7.43	7.43	7.43	0.00	0.00 %	0	9	-
160.00	5.78	5.78	5.78	5.78	0.00	0.00 %	0	12	-
165.00	2.00	6.30	3.92	4.15	0.00	0.00 %	0	35	-
170.00	6.00	6.00	6.00	6.00	0.00	0.00 %	0	151	-
175.00	2.10	2.10	2.10	2.10	0.00	0.00 %	0	15	-
180.00	0.65	0.65	0.65	0.65	0.00	0.00 %	0	20	-
185.00	0.05	4.00	1.20	2.025	0.00	0.00 %	0	16	-
190.00	0.05	2.90	0.50	1.475	0.00	0.00 %	0	28	-
195.00	1.91	1.91	1.91	1.91	0.00	0.00 %	0	17	-
200.00	0.61	0.61	0.61	0.61	0.00	0.00 %	0	35	-

Professional-Grade Tools, for Individual Investors.

Puts

Strike	Bid Price	Ask Price	Last Price	Midpoint	Change	Change %	Volume	OPEN INT	Last Trade
105.00	1.75	1.90	1.75	1.825	0.00	0.00 %	0	1	-
110.00	0.00	4.70	0.00	0.00	0.00	0.00 %	0	0	-
115.00	3.00	1.00	3.00	2.00	0.00	0.00 %	0	1	-
120.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
125.00	0.10	5.00	0.98	2.55	-0.71	-42.01 %	65	1	2/14/2025
130.00	1.60	1.60	1.60	1.60	0.00	0.00 %	0	1,003	-
135.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
140.00	1.65	1.65	1.65	1.65	0.00	0.00 %	0	10	-
145.00	2.75	2.75	2.75	2.75	0.00	0.00 %	0	1	-
150.00	7.22	7.22	7.22	7.22	0.00	0.00 %	0	1,001	-
155.00	7.50	7.50	7.50	7.50	0.00	0.00 %	0	4	-
160.00	11.00	15.00	3.80	13.00	0.00	0.00 %	0	504	-
165.00	14.50	18.50	4.30	16.50	0.00	0.00 %	0	1	-
170.00	18.00	22.50	14.20	20.25	0.00	0.00 %	0	5	-
175.00	22.50	26.50	14.00	24.50	0.00	0.00 %	0	3	-
180.00	26.50	31.00	23.85	28.75	0.00	0.00 %	0	22	-
185.00	31.00	35.00	22.84	33.00	0.00	0.00 %	0	0	-
190.00	36.00	40.00	29.16	38.00	0.00	0.00 %	0	1	-
195.00	40.50	44.50	0.00	42.50	0.00	0.00 %	0	0	-
200.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
JTAIJet AI Inc	$ 6.02 (133.33%)	101.64M
SRMSRM Entertainment Inc	$ 0.6999 (95.50%)	248.48M
WRDWeRide Inc	$ 31.4877 (83.39%)	20.57M
INLFINLIF Limited	$ 16.27 (80.58%)	7.67M
MBRXMoleculin Biotech Inc	$ 2.1201 (66.94%)	134.88M
BLACBellevue Life Sciences Acquisition Corporation	$ 3.08 (-56.31%)	425.19k
BLACUBellevue Life Sciences Acquisition Corporation	$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	$ 19.0001 (-49.58%)	1.01M
NEXNNexxen International Ltd	$ 10.30 (-49.16%)	160.99k
BSLKBolt Projects Holdings Inc	$ 0.6626 (-46.13%)	13.07M
CNSPCNS Pharmaceuticals Inc	$ 0.1415 (31.26%)	489.28M
MGOLMGO Global Inc	$ 0.7176 (-15.08%)	417.31M
SRMSRM Entertainment Inc	$ 0.6999 (95.50%)	254.39M
INTCIntel Corporation	$ 23.60 (-2.20%)	230.26M
NVDANVIDIA Corporation	$ 138.85 (2.63%)	194.99M

Monksdream

Monksdream 4 months ago

KRYS. Under $200

Monksdream

Monksdream 7 months ago

KRYS new 52 week high

Monksdream

Monksdream 9 months ago

KRYS 10Q due 5/6

Monksdream

Monksdream 10 months ago

Monksdream

Monksdream 11 months ago

KRYS new 52 week high

Monksdream

Monksdream 2 years ago

From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.

wiredawg

wiredawg 3 years ago

Moving nicely today...

wiredawg

wiredawg 3 years ago

Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?

wiredawg

wiredawg 3 years ago

In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

wiredawg

wiredawg 3 years ago

30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering

wiredawg

wiredawg 3 years ago

29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering

wiredawg

wiredawg 3 years ago

29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal

wiredawg

wiredawg 3 years ago

This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.

wiredawg

wiredawg 3 years ago

Holding well so far, why the pretty hard drop?

wiredawg

wiredawg 3 years ago

Why are you surprised? Serious question, not being impudent...

rynlrt

rynlrt 3 years ago

200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens

Fofo812

Fofo812 3 years ago

Surprised it held up this long

crudeoil24

crudeoil24 3 years ago

Large tutes holdings. Some taking huge gains before years end.

rynlrt

rynlrt 3 years ago

Not sure this kind of gain is sustainable. May see a big pullback

Fofo812

Fofo812 3 years ago

crudeoil24

crudeoil24 3 years ago

Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.

Trophy

Trophy 5 years ago

Krystal Biotech

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions